![]() ![]() Nuclear Regulatory Commission, making it the first and only of its kind that garnered approval for a small modular reactor. ![]() The company’s flagship product is its VOYGR small modular reactor which uses pressurized water technology to produce nuclear energy. Small modular reactors are advanced nuclear power plants with a much smaller footprint than conventional reactors. Nuscale Power (NYSE: SMR ) provides small modular nuclear reactor technology with the goal of carbon-free energy. This may offer a unique buying opportunity for investors looking to expand their portfolios and invest in the nuclear industry. This has turned many different countries away from pursuing an energy future using nuclear energy, fearing what could go wrong if a disaster similar to the ones mentioned would occur in other countries.īelow I will discuss three different stocks in the nuclear industry that have seen their share price fall over the last year from a number of factors, including reduced uranium mining operations and recent financial instability. There have always been tons of public criticism regarding the overall efficacy and safety of nuclear power, which stems from the nuclear disaster in Chernobyl in 1986 and the Fukushima disaster in 2011. These companies are focused on alternative energy sources that are much better for the planet’s environmental health on a large scale. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.There are few stocks that revolve around the nuclear industry, whether it is uranium mining or developing power plants. They also secured access to more cash through a loan, which is great for their future plans.Īs of this writing, Gabriel Osorio-Mazzilli did not hold (either directly or indirectly) any positions in the securities mentioned in this article. They have $246.5 million in cash on hand through March 31, 2023. But, there was a $3.3 million decrease in sales due to changes in the distribution of the product in the United States.Īlthough they reported a net loss of $11.2 million in the first quarter of 2023, they are in a good financial position. They also received an extra $300 thousand in royalties from Sunosi sales. In the first quarter of 2023, they had total revenues of $94.6 million.ĭuring that time, they sold $15.7 million of the product called Auvelity and $12.9 million of Sunosi. They are truly focused on developing and selling cancer therapies, and are committed to continue to advance their pipeline and remain a major player in the biotech industry.Īxsome Therapeutics (NASDAQ: AXSM) is a company dedicated to developing new treatments for central nervous system problems. This is slightly less than what they earned in the same period last year, but they are still in a strong financial position.Įxelixis shares non-GAAP financial measures, excluding certain expenses, to help investors better understand their performance. Despite these expenses, Exelixis still managed to earn GAAP net income of $40 million in the first quarter of 2023. Their research and development expenses increased because they invested more in licensing, collaborations, hiring more people and manufacturing. Their main source of revenue growth came from higher sales and pricing of their products. They are doing quite well and reported total revenues of $408.8 million in the first quarter of 2023, which is more than they earned during the same period in 2022. Exelixis (NASDAQ: EXEL) is a company that focuses on treating cancer with their lead product, cabozantinib. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |